Twist Bioscience CEO Calls $100 Million AI Forecast 'Guaranteed' As Analysts Press On Growth

Management sees upside beyond its initial fiscal 2027 outlook, with more manufacturing capacity needed to capture part of it.

Share
Twist Bioscience CEO Calls $100 Million AI Forecast 'Guaranteed' As Analysts Press On Growth

Twist Bioscience, which makes synthetic DNA and tools for biological research, defended its $100 million AI drug-discovery revenue forecast on Thursday's earnings call. Chief Executive Officer and Co-Founder Emily Leproust called the amount "guaranteed"; the company's initial fiscal 2027 outlook includes $100 million from that business, according to its results release.

A Forecast Below Management's Ambition

AI drug-discovery revenue rose 175% to $59.1 million in fiscal 2026 from $21.5 million a year earlier. Orders more than doubled. Analysts from Guggenheim and Leerink Partners pressed management on why the next year's initial revenue forecast implied slower growth.

"What we can take to the bank today, guaranteed, is $100 million," Leproust said in response to the Leerink Partners analyst. She also expressed confidence that Twist could "deliver triple-digit percentage growth in orders and revenue for fiscal 27."

Chief Financial Officer Adam Laponis said the initial forecast reflects customer programs and delivery schedules management believes it can convert into revenue with high confidence. Larger existing programs and new customers offer opportunities beyond that outlook.

Twist expects total fiscal 2027 revenue of $550 million to $560 million, approximately 21% growth at the midpoint. Fiscal 2026 revenue rose 22% to $459.4 million; fourth-quarter sales increased 28% to $126.6 million, marking its 15th consecutive quarter of growth from the preceding quarter.

From Pilots To Repeat Discovery

Twist's silicon-chip platform makes custom DNA for researchers, drugmakers and diagnostic companies. For AI customers, it can turn designs into DNA, produce proteins and test their properties, supplying experimental data that customers use to improve their models. Customers can buy individual parts of that process or the full service.

Leproust described an 18-month pattern across customer groups: pilot orders of $10,000 to $100,000 precede model-building purchases often worth multiple millions of dollars. Customers spend a quarter or more working with the resulting data before returning for drug-discovery experiments.

Those repeat purchases typically run from $250,000 to $1 million. Customers test successive designs until antibodies are ready for preclinical development, then begin again with a different target. Leproust said ongoing discovery revenue generally exceeds the initial model-building revenue for a customer.

Laponis said the customer pool includes large pharmaceutical companies, AI-focused drug developers and some major technology companies, but predominantly depends on existing customers focused on drug discovery.

In response to an Evercore ISI analyst, Leproust committed to reporting AI revenue through fiscal 2027. Traditional drugmakers' growing use of AI makes the boundary harder to draw, she said, so reporting only clearly identifiable AI activity may undercount the business.

Capacity Comes Before Revenue

Laponis expects approximately $150 million of capital spending across fiscal 2027 and fiscal 2028, plus more than $30 million of landlord-funded improvements. Management expects the investment to equip existing facilities to support more than $1 billion in annual revenue at scale.

Twist raised approximately $425 million through an equity offering and market sales. Leproust tied that summer fundraising to the capacity rollout. The company ended fiscal 2026 with approximately $582 million in cash, cash equivalents and short-term investments.

Protein and antibody manufacturing capacity increased almost 200% over the past 12 months, Leproust said. Twist plans another fivefold expansion for many protein-characterization tests relative to its fiscal 2026 exit capacity, including another lab inside its Oregon facility.

President and Chief Operating Officer Patrick Finn said Twist has 10 DNA writers operating, with two installations planned and four more ordered. With all 16 running, he expects daily capacity above 50 million pieces of DNA.

The expansion also carries costs before equipment reaches planned utilization. Twist expects fiscal 2027 gross margin of approximately 52.5% to 53%, versus 52.4% in fiscal 2026, and positive adjusted earnings before interest, taxes, depreciation and amortization for the year. Its fourth-quarter adjusted result was positive $2.2 million, alongside a $20.6 million net loss.

Leproust said capacity is being added every week. Capturing part of the upside she described depends on making room for the customer programs Twist wants to sell.

Sources

More on Twist Bioscience

All Twist Bioscience (TWST) coverage →